Cephalon Inc.: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Cephalon in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Cephalon's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights

Strategic insight into the prospects for Cephalon over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark Cephalon's performance against key rivals in the prescription pharmaceutical sector* Assess the effects of the patent expiry of Provigil on the company* See how two products, Treanda and Amrix, will generate new growth for the company in new therapy areas.

[Studien Infos ausblenden]

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Financial performance, 2003–15
Cephalon: PharmaVitae forecasts at a glance
Strategic insight
Generic sales erosion of key products only slightly offset by product lifecycle management strategies
More Acquisitions part of Cephalon’s key strategy for the forecast period
Cephalon’s lifecycle management strategy: generics have the final word
The CNS therapy area is one undergoing significant generic sales erosion
Cephalon acquires in order to diversify
SWOT analysis
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest quarterly sales
Latest comment
Q1 2009
Latest prescription pharma product news
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Latest corporate news
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Future product milestones
COMPANY INTRODUCTION
Key findings
Key corporate developments
[Missing title]
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009–15
Core analysis, 2009–15
Expiry analysis, 2009–15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002–08
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
KEY PRODUCTS AND COMPETITORS
Key findings
Overview
Central nervous system
Provigil
Nuvigil
Actiq
Fentora
Oncology
Treanda
Immunology and Inflammation
[Missing title]
Lupuzor
APPENDIX
Abbreviations

[Inhaltsverzeichnis ausblenden]